 Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The companys lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for autoimmunity. 